US2012196911A1PendingUtilityA1

Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same

53
Assignee: HEIDELBAUGH TODD MPriority: Sep 28, 2004Filed: Apr 16, 2012Published: Aug 2, 2012
Est. expirySep 28, 2024(expired)· nominal 20-yr term from priority
Inventors:Todd M. HeidelbaughKen ChowPhong X. NguyenDaniel W. GilJohn E. DonelloMichael E. GarstLarry A. WheelerJohn R. Cappiello
A61P 7/12A61P 9/12A61P 9/10A61P 9/04A61P 39/00A61P 37/00A61P 35/04A61P 7/10A61P 9/00A61P 3/08A61P 37/02A61P 37/06A61P 25/00A61P 31/12A61P 3/04A61P 25/22A61P 25/32A61P 25/30A61P 27/02A61P 29/00A61P 27/06A61P 31/10A61P 25/06A61P 25/28A61P 25/04A61P 31/02A61P 25/02A61P 25/18A61P 31/06A61P 31/18A61P 33/04A61P 29/02A61P 25/24A61P 25/16A61P 35/00A61P 19/06A61P 21/00A61P 1/04A61K 31/4166A61P 17/04A61P 17/02A61P 19/02A61P 1/12A61P 15/10A61P 17/06A61P 13/02A61P 11/02A61P 21/02C07D 233/84A61K 31/4174
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compounds of Formula 1 where the variables have the meaning defined in the specification are used to activate alpha 2 adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha 2 adrenergic receptors.

Claims

exact text as granted — not AI-modified
1 . A method comprising administering to a mammal a pharmaceutical composition containing a therapeutically effective dose of a compound for the treatment of altered function of the immune system such as autoimmune diseases including lupus erythematosis, dry eye disorders, rheumatoid arthritis, spondylitis, gouty arthritis, osteoarthritis, juvenile arthritis; said compound having a structure selected from 
       
         
           
           
               
               
           
         
       
     
     
         2 . A method in accordance with  claim 1  where the pharmaceutical composition is administered to the mammal for lupus erythematosis. 
     
     
         3 . A method in accordance with  claim 1  where the pharmaceutical composition is administered to the mammal for dry eye. 
     
     
         4 . A method in accordance with  claim 1  where the pharmaceutical composition is administered orally. 
     
     
         5 . A method in accordance with  claim 1  where the pharmaceutical composition is administered intraperitonially. 
     
     
         6 . A method in accordance with  claim 1  where the compound has the formula 
       
         
           
           
               
               
           
         
       
     
     
         7 . A method in accordance with  claim 1  where the compound has the formula 
       
         
           
           
               
               
           
         
       
     
     
         8 . A method in accordance with  claim 1  where the compound has the formula 
       
         
           
           
               
               
           
         
       
     
     
         9 . A method in accordance with  claim 1  where the compound has the formula 
       
         
           
           
               
               
           
         
       
     
     
         10 . A method in accordance with  claim 1  where the compound has the formula 
       
         
           
           
               
               
           
         
       
     
     
         11 . A method in accordance with  claim 2  where the pharmaceutical composition contains a therapeutically effective dose of a compound with the formula 
       
         
           
           
               
               
           
         
       
     
     
         12 . A method in accordance with  claim 2  where the pharmaceutical composition contains a therapeutically effective dose of a compound with the formula 
       
         
           
           
               
               
           
         
       
     
     
         13 . A method in accordance with  claim 2  where the pharmaceutical composition contains a therapeutically effective dose of a compound with the formula

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.